Bureaucrats, editor, reviewer, Administrators
6,381
edits
WikiJournalClub:High-priority articles: Difference between revisions
Jump to navigation
Jump to search
→Incomplete or nonexistent
(OPTION now usable) |
|||
| Line 11: | Line 11: | ||
* 2025 {{create article link|Advance-HTN}}: Lorundrostat (aldosterone synthase inhibitor) for uncontrolled HTN [https://www.nejm.org/doi/full/10.1056/NEJMoa2501440] | * 2025 {{create article link|Advance-HTN}}: Lorundrostat (aldosterone synthase inhibitor) for uncontrolled HTN [https://www.nejm.org/doi/full/10.1056/NEJMoa2501440] | ||
* 2025 {{create article link|API-CAT}}: Full vs. reduced dose apixaban for cancer-associated VTE secondary prevention [https://www.nejm.org/doi/full/10.1056/NEJMoa2416112] | * 2025 {{create article link|API-CAT}}: Full vs. reduced dose apixaban for cancer-associated VTE secondary prevention [https://www.nejm.org/doi/full/10.1056/NEJMoa2416112] | ||
* 2024 {{create article link|SABATO}}: IV then oral ABX for S. aureus [https://pubmed.ncbi.nlm.nih.gov/38244557/] | |||
* 2024 {{create article link|REVIVE}}: Rusfertide vs. placebo in PV [https://www.nejm.org/doi/full/10.1056/NEJMoa2308809] | * 2024 {{create article link|REVIVE}}: Rusfertide vs. placebo in PV [https://www.nejm.org/doi/full/10.1056/NEJMoa2308809] | ||
* 2023 {{create article link|Thalidomide for small intestine angiodysplasia}}: Thalidomide in angiodysplasia of the small intestine [https://www.nejm.org/doi/full/10.1056/NEJMoa2303706] | * 2023 {{create article link|Thalidomide for small intestine angiodysplasia}}: Thalidomide in angiodysplasia of the small intestine [https://www.nejm.org/doi/full/10.1056/NEJMoa2303706] | ||